ACM
NKTR icon

ADAR1 Capital Management’s Nektar Therapeutics NKTR Stock Holding History

ADAR1 Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,000
Closed -$904K – 247
2025
Q2 		$904K Buy
+35,000
New +$393K 0.14% 89

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ADAR1 Capital Management's NKTR Position: Q1 2026 in Review

ADAR1 Capital Management increased its Nektar Therapeutics (NKTR) stake by 124% in Q1 2026, buying an estimated $5.08M and bringing the position to 161,252 shares worth $11.6M. The position accounts for 0.68% of the portfolio, ranked #40.

ADAR1 Capital Management first reported a position in NKTR in Q3 2024 and has held it in 7 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • ADAR1 Capital Management held 161,252 shares of Nektar Therapeutics worth $11.6M as of Q1 2026.
  • ADAR1 Capital Management bought 89,221 Nektar Therapeutics shares in Q1 2026, an estimated $5.08M.
  • Nektar Therapeutics made up 0.68% of ADAR1 Capital Management's portfolio in Q1 2026, its #40 holding.
  • ADAR1 Capital Management first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.